Technology in Cancer Research & Treatment最新文献

{"title":"Dosimetric and Geometric Analysis for MLC Based and Iris Based Treatment Plans: A Retrospective Study for Intracranial Tumors with Cyberknife Device.","authors":"Jiaxin Wang, Bo Yang, Tingtian Pang, Zhiqun Wang, Yue Zhang, Xia Liu, Jie Qiu","doi":"10.1177/15330338251388215","DOIUrl":"https://doi.org/10.1177/15330338251388215","url":null,"abstract":"<p><p>PurposeIn our institute, stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (SRT) were performed by Cyberknife-S7 (CK-S7) which provided the selection of different collimators. This study aimed to compare critical plan qualities including conformality, high-dose area, dose fallout, and treatment efficiency between InCise™ multileaf collimator (MLC) based and Iris™ variable aperture collimators (Iris) based treatment plans.MethodsTwenty-five patients with intracranial tumors treated with CK-S7 were retrospectively analyzed. The Precision 3.3.0.0 with VOLO™ optimizer and GPU-accelerated Monte Carlo dose calculation algorithm was used for treatment planning. The new conformality index (nCI), homogeneity index (HI), high-dose ratio (HDR) and distribution inside plan target volume (PTV), dose gradient distance (DGD) outside PTV, organs at risk (OARs) sparing, and treatment efficiency were compared between MLC based and Iris based plans.ResultsMLC plan achieved higher nCI, higher HDRs from 135% prescription dose (PD) to 110%PD and trended to form more centralized and gathered high-dose distribution inside PTV, while no statistical difference was found in HI. Iris possessed better dose-engraving ability around the target boundary especially when it close to OARs with strict dose constraints. MLC plan showed shorter DGD from 90%PD to 20%PD. MLC plan achieved less MUs (-67.14%), less nodes (-41.5%), less beams (-74.06%) and shorter treatment time (-51.64%). There were positive correlations between the effective radius of PTV (rPTV) and DGD from 90%PD to 10%PD both in MLC and Iris plans.ConclusionsMLC plan achieved comparable conformality, higher HDRs, more gathered high-dose distribution, faster dose fallout and more efficient treatment which proved it an excellent SRS/SRT choice for intracranial tumors treated with CK-S7. MLC might take an important advantage for the uncompliant and painful patients. However, Iris showed a better dose-engraving ability, it might be taken into consideration especially when the tumor was close to OARs with strict dose constraints.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251388215"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145347448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy Analysis of Hypofractionated Radiotherapy for Oligometastatic Tumors: A Retrospective Study.","authors":"Qian Sun, Hanqing Zhao, Xianwen Zhang, Suli Zhang, Zelai He, Gengming Wang, Hao Jiang, Aili Xuan, Xianming Li","doi":"10.1177/15330338241310155","DOIUrl":"10.1177/15330338241310155","url":null,"abstract":"<p><strong>Introduction: </strong>Metastasis remains a major cause of death among patients with malignant tumors. Radiotherapy is one of the main modalities of cancer treatment. The rapid development of radiotherapy technology has enabled the widespread application of hypofractionated radiotherapy (HFRT) in clinical practice. This study aimed to evaluate the effect of HFRT on the survival and safety of patients with oligometastatic tumors.</p><p><strong>Methods: </strong>We conducted a retrospective study that involved 65 patients with well-controlled primary tumors and 1-5 metastatic foci treated at the study site between January 2020 and December 2022. Patients were aged >18 years and had a ≥ 6-month life expectancy. The patients received standard treatments plus HFRT for all metastatic foci. The dose fractionation regimen was adjusted according to the location and size of the patient's metastatic foci. The planning gross tumor volume of HFRT was 82.93 cm³ (range: 10.12-562.80 cm³), and the radiation dose range was 20 Gy/5 F-60 Gy/15 F. Progression-free survival (PFS), overall survival (OS), local control rates, and incidence of adverse events of the patients were observed.</p><p><strong>Results: </strong>Among the 65 patients, the median follow-up time, PFS, and OS were 26 months (95% CI: 0.80-37.50), 15 months (95% CI: 9.36-20.64), and 28 months (95% CI: 16.71-39.29), respectively. The 1- and 2-year PFS were 53.8% and 40.0%, respectively, while the 1- and 2-year OS rates were 73.8% and 56.9%, respectively. In total, 13.8%, 55.4%, 20.0%, and 13.8% of patients showed complete response, partial response, stable disease, and progressive disease, respectively. Four patients developed grade 3 or worse adverse events, and no treatment-related deaths occurred.</p><p><strong>Conclusions: </strong>HFRT showed favorable clinical efficacy and safety in patients with oligometastatic tumors, generally achieving a good OS rate. Further randomized trials should be conducted.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241310155"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular Volume Derived from Equilibrium CT for the Prediction of Survival Outcomes in Patients with Pancreatic Ductal Adenocarcinoma.","authors":"Ju Xiong, Yunfeng Lu, Haotian Liu, Mengchu Ji, Zhiwei Zhang, Yongmei Li, Hongwei Liang","doi":"10.1177/15330338251336032","DOIUrl":"https://doi.org/10.1177/15330338251336032","url":null,"abstract":"<p><p>ObjectiveTo assess the efficiency of extracellular volume (ECV) derived from equilibrium computed tomography (CT) in predicting recurrence-free survival (RFS) and overall survival (OS) after R0 resection of pancreatic ductal adenocarcinoma (PDAC).MethodsThis retrospective study included 83 patients who underwent CT and R0 resection between January 2016 and September 2023. The pattern of tumor recurrence and prognosis were recorded for each patient. Tumor recurrence was classified into three groups: isolated local recurrence group, distant recurrence group and censored group. The associations between the CT-ECV and clinicopathological features and recurrence pattern of PDAC were evaluated by chi-squared test. Multivariable Cox proportional-hazards models were conducted to evaluate the effects of clinical factors, CT features and CT-ECV on RFS and OS.ResultsThe median RFS and OS were 10.7 and 17.1 months, respectively. On multivariate analysis, the CT-ECV and adjacent organ invasion were found to be associated with RFS (HR, 0.968, <i>P</i> = .017; HR, 0.453; <i>P</i> = .006), and only the CT-ECV was an independent prognostic factor for OS (HR, 0.968; <i>P</i> = .022). Low CT-ECV group was significantly associated with elevated CA19-9, larger tumor size, G3 (tumor grade) and II/III (AJCC tumor stage) (<i>P</i> < .05). In the recurrence pattern analysis, the CT-ECV did not exhibit an association between local recurrence and non-local recurrence groups (<i>P</i> = .455), while patients in the low CT-ECV group were more inclined to experience distant recurrence after curative surgery (<i>P</i> = .037).ConclusionsCT-ECV determined by equilibrium contrast-enhanced CT was a useful imaging biomarker for predicting distant recurrence and survival in resectable PDAC patients, which may facilitate further risk stratification and personalized care.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251336032"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).","authors":"Ya-Nan Wang, Chao-Wei Zhang, Yu-Xuan Gao, Xue-Ling Ge","doi":"10.1177/15330338251321349","DOIUrl":"10.1177/15330338251321349","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a malignant hematological disease originating from plasma cells that remains incurable. Autologous stem cell transplantation (ASCT) is an important treatment method for MM. With the development of new drugs, the treatment of MM patients who meet the ASCT criteria has significantly improved, and the median survival time has increased by 8-10 years. The current treatment for MM patients who meet the ASCT criteria consists mainly of the following stages: induction therapy, stem cell collection, stem cell transplantation, and consolidation and maintenance therapy. Even today, long-term disease control remains the goal of MM treatment in clinical practice. In the era of new drugs, early ASCT still results in longer progression-free survival (PFS) and is currently the standard treatment method for young newly diagnosed multiple myeloma (NDMM) patients. Moreover, tandem transplantation can be considered for MM patients with high-risk cytogenetics. This review discusses mainly the role of ASCT in MM, the conditions for patient transplantation, the induction chemotherapy regimen before transplantation, the conditioning regimen, the timing of transplantation, and the effectiveness of tandem transplantation, including maintenance and salvage ASCT after transplantation.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251321349"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Inhibition of Mircorna-766-5p Attenuates the Development of Cervical Cancer Through Regulating SCAI.","authors":"","doi":"10.1177/15330338251363342","DOIUrl":"10.1177/15330338251363342","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251363342"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy.","authors":"Qiange Zhang, Ying Liu, Hanqin Xuan, Shenghua Zhan, Yu Shen, Ruipeng Wang, Siji Chen, Sisi Ding, Cuiping Liu, Lili Huang, Qi Ma, Tingwang Jiang, Lei Cao","doi":"10.1177/15330338251380957","DOIUrl":"10.1177/15330338251380957","url":null,"abstract":"<p><p>IntroductionGastric cancer (GC) is a highly heterogeneous malignancy, necessitating novel therapeutic targets. B7-H3 and CD39, as immune checkpoints, are potential modulators of the tumor microenvironment and may influence the efficacy of immunotherapies.MethodsB7-H3, CD39, and CD8 expression was assessed via immunohistochemistry (IHC) in 268 GC tissues and 80 gastric precancerous lesions. The correlation between B7-H3 and CD39 expression was analyzed using Spearman's correlation. Multiplex immunohistochemistry (m-IHC) was employed to determine the co-localization of B7-H3 and CD39 in GC tissues. Kaplan-Meier survival analysis and Cox regression models were utilized to evaluate clinical outcomes in different patient subgroups.ResultsBoth B7-H3 and CD39 expression showed a stepwise increase during gastric carcinogenesis including chronic superficial gastritis (CSG), chronic atrophic gastritis (CAG), low-grade intraepithelial neoplasia (LGIN), high-grade intraepithelial neoplasia (HGIN) to GC, with significantly higher expression levels in GC tissues compared to all precancerous lesions (<i>P</i> < .05). A significant positive correlation was observed between B7-H3 and CD39 expression (r = 0.2398, <i>P</i> < .001). Co-localization of B7-H3 and CD39 was detected within tumor nests and peritumoral regions and was significantly correlated with tumor volume (<i>P</i> = .017), tumor stage (<i>P</i> = .001), tumor depth (<i>P</i> = .002), lymph node metastasis (<i>P</i> = .005), lymph node involvement (<i>P</i> = .004) and distant metastasis (<i>P</i> = .028). Kaplan-Meier analysis revealed that patients with co-localized B7-H3 and CD39 expression exhibited significantly poorer prognosis (<i>P</i> = .0055). Cox regression analysis confirmed that this co-localization was a significant predictor of survival (<i>P</i> = .007) and an independent prognostic factor in multivariate analysis (<i>P</i> = .027).ConclusionThe co-localized expression of B7-H3 and CD39 in GC patients is strongly associated with poor prognosis. This dual-target expression pattern provides novel insights and a theoretical foundation for the development of dual-target immune checkpoint inhibitors as potential therapeutic strategies.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251380957"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145132055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Cavity Squamous Cell Carcinoma: Impact of Clear Margin Distance on Locoregional Control in Patients Undergoing Postoperative Radiotherapy.","authors":"Erkan Topkan, Efsun Somay, Ugur Selek","doi":"10.1177/15330338241305823","DOIUrl":"10.1177/15330338241305823","url":null,"abstract":"<p><p>We congratulate Lang and colleagues for their study investigating the impact of resection margin (RM) size on locoregional control (LC) outcomes, overall survival (OS), progression-free survival (PFS), and treatment-related toxicity in 162 patients with oral cavity squamous cell carcinoma (OCSCC) who received postoperative radiotherapy (PORT).1 In this study, 77 (47.5%), 22 (13.6%), and 63 (38.9%) patients had involved (5 mm) RM, respectively. A RM of ≤5 mm was found to be a significant predictor for worse LC (HR 2.6), but not for OS (HR 1.2) or PFS (HR 1.2). The findings of this study provide important insights into how the status of RM affects the local control and survival outcomes of OCSCC patients who undergo PORT. However, we have two concerns that we believe need to be addressed to interpret the results more comprehensively and guide future research on this critical topic.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241305823"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiation and Localization of Adjacent Murine Tumors Using X-ray and Bioluminescence Tomography.","authors":"Jiahao Chen, Yunwen Huang, Ning Zhao, Yi Ru, Yidong Yang","doi":"10.1177/15330338251382977","DOIUrl":"10.1177/15330338251382977","url":null,"abstract":"<p><p>IntroductionPreviously, a multimodal imaging system including x-ray computed tomography (CT) and bioluminescence tomography (BLT) has been developed on iSMAART and is capable of accurately localizing small tumors on the millimeter scale in three dimensions (3D). Here, a \"2D decomposition + 3D reconstruction\" strategy is proposed to recover multiple tumors that are closely spaced and may have drastically different bioluminescence intensities.MethodsIn the iSMAART system, CT provides the animal anatomy and surface contours required for BLT reconstruction. The BLT and CT are physically registered, rendering superimposed images. For BLT reconstruction, the surface bioluminescence signal is first decomposed using a Gaussian mathematical model into multiple independent signal distributions, before separate reconstruction of individual targets. The final tumor distribution is the summation of the individual reconstruction results. BLT/CT imaging was performed on two types of metastatic tumor models, PC3 prostate tumors and HCT116 colorectal tumors, with 2 mice in each model. A double-blind histopathological analysis was conducted to verify the imaging results.Results and ConclusionBy incorporating the proposed strategy, the iSMAART system accurately differentiated and localized multiple tightly clustered tumors of varying sizes and optical intensities in all mice, and four tumors in a single mouse were simultaneously diagnosed. The tumor sizes measured by BLT closely matched the histopathological results (mean value 2.76 vs 2.41 mm). In this study, we proposed a \"2D decomposition + 3D reconstruction\" strategy, which enables the iSMAART system to accurately localize and quantify multiple tumors in live animals despite significant signal overlap and intensity variations, providing a powerful tool to fulfill and even open up more high-demand research fields.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251382977"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12480804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145193071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiomics-Based Machine Learning for Determining <i>MYCN</i> Amplification Status in Childhood Neuroblastoma: A Systematic Review and Meta-Analysis.","authors":"Haoru Wang, Yi Ji, Xin Chen, Ling He, Xiangming Fang, Jinhua Cai","doi":"10.1177/15330338251358324","DOIUrl":"10.1177/15330338251358324","url":null,"abstract":"<p><p>IntroductionThe <i>MYCN</i> oncogene promotes tumor cell proliferation in neuroblastoma, and its amplification is a well-established marker of poor prognosis. Radiomics-based approaches have shown promise in noninvasively determining <i>MYCN</i> amplification status; however, their diagnostic performance has varied significantly across studies. This systematic review and meta-analysis aimed to quantitatively evaluate the diagnostic accuracy of radiomics-based machine learning models for determining <i>MYCN</i> amplification in neuroblastoma and to critically assess the methodological quality of the included studies.MethodsA systematic search of articles published between January 1, 2000, and June 30, 2024, was conducted across PubMed, Embase, Web of Science, and the Cochrane Library. The articles focused on using radiomics to determine <i>MYCN</i> amplification in neuroblastoma. Methodological quality was assessed using the Radiomics Quality Score (RQS), METhodological RadiomICs Score (METRICS), and Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tools. A meta-analysis of validation performance was performed on studies with Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis statement Type 2a or higher.ResultsNine studies with 851 patients were included, and seven studies with 217 patients in the validation set were eligible for meta-analysis. The RQS scores ranged from 10 to 16 (mean 12), and METRICS scores ranged from 28.8% to 78.4% (mean 59.7%). QUADAS-2 assessment indicated that most studies had a low or unclear risk of bias. The pooled sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio were 0.78, 0.92, 9.45, and 0.24, respectively. The area under the summary receiver operating characteristic curve was 0.94 (95% confidence interval: 0.91-0.95).ConclusionDespite variability in study design and bias risk, radiomics shows promise as a non-invasive method for detecting <i>MYCN</i> amplification in neuroblastoma. Further refinement and validation in multicenter studies with larger sample sizes are needed to enhance its clinical applicability.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251358324"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2-Targeted Nanoliposome Therapy Activates Immune Response by Converting Cold to Hot Breast Tumors.","authors":"Quan Sun, Ying Zhu, Dongli Zhao, Lili Yang, Siyu Zhang, Changxin Huang","doi":"10.1177/15330338251356387","DOIUrl":"10.1177/15330338251356387","url":null,"abstract":"<p><p>IntroductionHER2-positive breast cancer, accounting for 15%-20% of cases, remains challenging due to therapy resistance and immunosuppressive \"cold tumor\" microenvironments. Current strategies combining immunotherapy with chemotherapy or radiotherapy often face toxicity limitations. To address this, we developed HER2-targeted nanoliposomes co-delivering viral peptides and the STING agonist diABZI, aiming to convert cold tumors into immunologically active \"hot tumors\" by enhancing antigen spreading and immune recognition.MethodsViral peptides with high Human Leukocyte Antigen-A2 affinity were selected using NetMHCpan-4.1/4.0 and incorporated into nanoliposomes via thin-film dispersion. Trastuzumab F(ab')₂ fragments were conjugated for HER2-specific targeting. Nanoliposomes were characterized for size, stability, encapsulation efficiency (HPLC), and in vitro release. Immune efficacy was assessed via ELISPOT, flow cytometry (CD3+/CD8+/NK cells), and TCR β sequencing in HER2⁺ SK-BR-3 and HER2^- MCF-7 cells. Cytotoxicity and cellular uptake were evaluated using CCK-8 assays and fluorescence imaging.ResultsThe nanoliposomes exhibited uniform size (∼70 nm), stability (5% size variation over 25 days), and high encapsulation efficiency (75.5% for peptides). Targeted delivery to SK-BR-3 cells peaked at 60 µL (<i>P</i> < .05), with sustained release of peptides (52% at 48 h) and diABZI (46.2%). In HER2⁺ cells, nanoliposomes synergistically enhanced IFN-γ (2.5-fold, <i>P</i> < .01) and granzyme B (3-fold, <i>P</i> < .05) secretion, overcoming antagonism seen with free agents. Flow cytometry revealed dominant CD8⁺ T-cell infiltration (50.9% vs 0.67% in controls) and expanded NK/NKT populations. TCR β sequencing showed increased clonotype diversity (60,915 vs 57 574 clones) and reduced clonal dominance, indicating broadened antigen recognition.ConclusionOur HER2-targeted nanoliposomes effectively reprogrammed cold tumors by dual activation of innate (STING pathway) and adaptive (viral peptide-driven TCR diversity) immunity. The platform demonstrated robust targeting, safety, and immune activation, offering a promising strategy to overcome immunotherapy resistance. Future studies will validate in vivo efficacy and explore adaptations for other cold tumors via alternative targeting ligands.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251356387"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144601688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}